为了防止尿液的反复保留,Medicus Pharma将Teverelix的第二阶段方案提交给FDA. Medicus Pharma submits Phase 2 protocol for Teverelix to FDA to prevent recurrent urinary retention.

医药公司已向美国FDA提交了针对Teverelix的优化第二期临床试验方案. Medicus Pharma has submitted an optimized Phase 2 clinical trial protocol for Teverelix to the U.S. FDA. 治疗目的是防止男性良性前列腺增生再次发生急性尿. The therapy aims to prevent recurrent acute urinary retention in men with benign prostatic hyperplasia. 该公司强调了研究设计的改进,以加强疗效和安全性评估. The company highlighted improvements to the study design to enhance efficacy and safety evaluation.